GlassScriptPhysician profile
Julia Wuest
NPI 1740863125
$2,760.25
in general payments reported to CMS, 2019-2025
18 companies · $870 in 2025
The $870 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $304 · 2023: $430 · 2024: $962 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Education: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.47 |
| Education | $876.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $655.89 | 2023-2025 | Darzalex, Carvykti, Tecvayli |
| Astellas Pharma US INC | $602.24 | 2021-2025 | Xospata, Cresemba |
| Celgene Corporation | $244.84 | 2021-2025 | Reblozyl, Revlimid |
| Abbvie INC. | $244.19 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $215.96 | 2022-2025 | |
| Glaxosmithkline, LLC. | $135.51 | 2022-2025 | Ojjaara |
| Karyopharm Therapeutics INC. | $123.20 | 2023 | Xpovio |
| Janssen Scientific Affairs, LLC | $114.52 | 2023-2025 | Talvey, Tecvayli, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $100.43 | 2023 | Imbruvica, Epkinly |
| Incyte Corporation | $85.85 | 2025 | Pemazyre, Monjuvi |
| Genzyme Corporation | $53.30 | 2024-2025 | |
| Genentech USA, INC. | $40.82 | 2025 | Itovebi, Phesgo, Tecentriq Hybreza |
| Emd Serono, INC. | $27.89 | 2024 | |
| Azurity Pharmaceuticals, INC. | $25.18 | 2025 | Vivimusta |
| Beigene USA, INC. | $24.01 | 2024 | Brukinsa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $23.74 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.94 | 2023 | |
| Geron Corporation | $20.74 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Wuest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.